<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489368</url>
  </required_header>
  <id_info>
    <org_study_id>RGCIRC/IRB/80/2020</org_study_id>
    <nct_id>NCT04489368</nct_id>
  </id_info>
  <brief_title>Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence &amp; Machine Learning</brief_title>
  <acronym>QARC</acronym>
  <official_title>Pathological Response Prediction to Neo-adjuvant Chemoradiotherapy in Esophageal Carcinoma and Comparison of Engineered Features Versus Deep Learning Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Kundan Singh Chufal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajiv Gandhi Cancer Institute &amp; Research Center, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In esophageal carcinoma, neoadjuvant concurrent chemo-radiotherapy (NA-CCRT) followed by&#xD;
      surgery is the current standard of care and ample evidence has accumulated supporting the&#xD;
      view that complete pathological response (pCR) is a positive prognostic marker for improved&#xD;
      outcomes. Predicting the probability of achieving pCR prior to neoadjuvant treatment could&#xD;
      permit modification of treatment protocols for those patients unlikely to achieve pCR.&#xD;
&#xD;
      Radiomics is a new entrant in the field of imaging where specific features are derived from&#xD;
      the intensity and distribution pattern of pixels based on a region-of-interest (ROI). The&#xD;
      features thus extracted can then be used for prediction modelling similar to other -omics&#xD;
      datasets. Preliminary investigations examining its utility have been performed and its&#xD;
      applications have thus far focused on screening and survival prediction after treatment. Due&#xD;
      to the multi-dimensional nature of data extracted using radiomics, Artificial Intelligence&#xD;
      (AI) methods are ideally suited for analysing and modelling radiomic features.&#xD;
&#xD;
      Machine Learning (ML) and Deep Learning (DL)[utilising Convolutional Neural Networks (CNN)]&#xD;
      are both part of the AI framework. In contrast to ML, DL is a new entrant and has been&#xD;
      utilised by some medical researchers for modelling using prediction-type algorithms. Besides&#xD;
      significantly reducing the workflow associated with Radiomics-based research, feature&#xD;
      engineering and modelling using DL are immune to the effects of incorrect ROI delineation.&#xD;
      However, the main limitation of DL is the 'blackbox' effect, in which the underlying basis of&#xD;
      a CNN is not known. This has been mitigated in part by the visualisation of activation maps&#xD;
      directly on the image dataset to prove biological plausibility of predictions. The&#xD;
      comparative performance of both types of modelling is also not known.&#xD;
&#xD;
      Our objective is to investigate pCR probability in our study population using radiomics-based&#xD;
      ML and AI-based modelling. We will also investigate the comparative performance of both&#xD;
      modelling techniques. For DL based prediction modelling, we will attempt to provide&#xD;
      biological plausibility on the basis of activation maps.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Develop models to predict pCR based on pre-neoadjuvant imaging modalities</measure>
    <time_frame>August 2021</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy</measure>
    <time_frame>January 2020</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Patients undergoing NA-CCRT followed by Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neo-Adjuvant Radiotherapy</intervention_name>
    <description>Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neo-Adjuvant Chemotherapy</intervention_name>
    <description>Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagectomy</intervention_name>
    <description>Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient records in each participating research center from January 2011 to 1st May 2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status: 0-2&#xD;
&#xD;
          -  Patients with histopathological or cytopathological confirmed malignancy of the&#xD;
             esophagus&#xD;
&#xD;
          -  Histology: Squamous Cell Carcinoma and Adenocarcinoma&#xD;
&#xD;
          -  Patients should have received NeoAdjuvant Concurrent Chemoradiation (NACCRT) followed&#xD;
             by Surgery&#xD;
&#xD;
          -  All therapeutic interventions (Radiotherapy, Chemotherapy &amp; Surgery) delivered within&#xD;
             participating institutions&#xD;
&#xD;
          -  At least one pre-NACCRT DICOM imaging dataset (HRCT/ 18-FDG PET-CT/ Radiotherapy&#xD;
             planning CT) for each patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any metallic implants in the region of interest&#xD;
&#xD;
          -  Patient with locally advanced disease or metastatic disease (T4 disease, Fistula,&#xD;
             metastases)&#xD;
&#xD;
          -  Patients with prior history of radiotherapy in the same region&#xD;
&#xD;
          -  Patients developing a second malignancy in the esophagus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kundan S Chufal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajiv Gandhi Cancer Institute &amp; Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illawarra Cancer Care Centre</name>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute &amp; Research Center</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>India</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rajiv Gandhi Cancer Institute &amp; Research Center, India</investigator_affiliation>
    <investigator_full_name>Dr Kundan Singh Chufal</investigator_full_name>
    <investigator_title>Senior Consultant &amp; Chief of Thoracic Radiation Oncology, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Artificial Intelligence</keyword>
  <keyword>Deep Learning</keyword>
  <keyword>Neoadjuvant Chemoradiation</keyword>
  <keyword>Pathologic Response</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

